 <h1>Votrient Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>pazopanib</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about pazopanib. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Votrient.</p><h2>In Summary</h2><p><b>Common side effects of Votrient include:</b> bleeding tendency disorder, abdominal pain, decreased serum glucose, decreased serum magnesium, decreased serum phosphate, diarrhea, fatigue, hypertension, increased serum alanine aminotransferase, increased serum aspartate aminotransferase, increased serum bilirubin, leukopenia, nausea, neutropenia, thrombocytopenia, vomiting, and anorexia. <b>Other side effects include:</b> hypothyroidism, and proteinuria.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to pazopanib: oral tablet</i></p><h3>Warning</h3><p class="blackboxWarning-title">Oral route (Tablet)</p><p>Severe and fatal hepatotoxicity has occurred during clinical trials. Monitor hepatic function. Interrupt, reduce, or discontinue treatment as recommended.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, pazopanib (the active ingredient contained in Votrient) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking pazopanib:</p><p>
<i>More common</i>
</p><ul>
<li>Black, tarry stools</li>
<li>bleeding gums</li>
<li>blood in the urine or stools</li>
<li>blurred vision</li>
<li>chest pain</li>
<li>chills</li>
<li>clay colored stools</li>
<li>cloudy urine</li>
<li>constipation</li>
<li>cough</li>
<li>coughing up blood</li>
<li>dark urine</li>
<li>decreased appetite</li>
<li>depressed mood</li>
<li>difficulty with breathing or swallowing</li>
<li>dizziness</li>
<li>dry skin and hair</li>
<li>feeling cold</li>
<li>fever</li>
<li>hair loss</li>
<li>headache</li>
<li>hoarseness or husky voice</li>
<li>increased menstrual flow or vaginal bleeding</li>
<li>itching, skin rash</li>
<li>loss of appetite</li>
<li>lower back or side pain</li>
<li>muscle cramps and stiffness</li>
<li>nausea and vomiting</li>
<li>nervousness</li>
<li>nosebleeds</li>
<li>painful or difficult urination</li>
<li>pale skin</li>
<li>paralysis</li>
<li>pinpoint red spots on the skin</li>
<li>pounding in the ears</li>
<li>prolonged bleeding from cuts</li>
<li>red or black, tarry stools</li>
<li>red or dark brown urine</li>
<li>redness, swelling, or pain of the skin</li>
<li>scaling of the skin on the hands and feet</li>
<li>slow or fast heartbeat</li>
<li>sore throat</li>
<li>sores, ulcers, or white spots on the lips or in the mouth</li>
<li>stomach pain or tenderness</li>
<li>swelling of the feet or lower legs</li>
<li>swollen glands</li>
<li>tingling of the hands and feet</li>
<li>ulceration of the skin</li>
<li>unusual bleeding or bruising</li>
<li>unusual tiredness or weakness</li>
<li>weight gain</li>
<li>yellow eyes or skin</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Bleeding from the rectum or bloody stools</li>
<li>bloody nose</li>
<li>chest discomfort</li>
<li>confusion</li>
<li>fainting</li>
<li>irregular or slow heart rate</li>
<li>numbness or tingling in the face, arms, or legs</li>
<li>pain or discomfort in the shoulders, arms, jaw, back, or neck</li>
<li>sweating</li>
<li>swelling or puffiness of the face</li>
<li>trouble speaking, thinking, or walking</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of pazopanib may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Change in hair color</li>
<li>change in taste</li>
<li>decreased weight</li>
<li>diarrhea</li>
<li>hair loss</li>
<li>lack or loss of strength</li>
<li>loss of taste</li>
<li>thinning of the hair</li>
<li>weight loss</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Belching</li>
<li>heartburn</li>
<li>indigestion</li>
<li>stomach discomfort, upset, or pain</li>
</ul><p>
<!-- end oral tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to pazopanib: oral tablet</i></p><h3>Hepatic</h3><p>-ALT and AST elevations occurred early in the treatment course; 92.5% of all transaminase elevations of any grade occurred in the first 18 weeks.</p>
<p>-Hepatic failure was the cause of death for 0.2% of RCC patients and 0.4% of STS patients.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Increased ALT (up to 53%), increased AST (up to 53%), increased total bilirubin (up to 36%), increased alkaline phosphatase (up to 32%)</p>
<p><b>Common</b> (1% to 10%): Abnormal hepatic function, hepatotoxicity, decreased alkaline phosphatase, increased gamma-glutamyltransferase (GGT), abnormal liver function test </p>
<p><b>Uncommon</b> (0.1% to 1%): Jaundice, drug-induced liver injury, hepatic failure, increased hepatic enzyme</p>
<p><b>Postmarketing reports</b>: Increased GGT<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p>-A majority of the patients with myocardial dysfunction had concurrent hypertension which may have exacerbated cardiac dysfunction in patients at risk possibly by increasing cardiac afterload.</p>
<p>-Cardiac dysfunction included left ventricular dysfunction, cardiac failure, and restrictive cardiomyopathy.</p>
<p>-Venous thromboembolic events included deep vein thrombosis, pulmonary embolism, and thrombosis terms.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Hypertension (up to 42%), myocardial dysfunction (up to 11%), chest pain (up to 10%)</p>
<p><b>Common</b> (1% to 10%): Venous thromboembolic events, cardiac dysfunction, bradycardia, QT prolongation, myocardial infarction or ischemia, hot flush, flushing</p>
<p><b>Uncommon</b> (0.1% to 1%): Torsades de pointes, congestive heart failure, fatal arterial thromboembolic events, hypertensive crisis<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Tumor pain (up to 32%), hemorrhagic events (up to 13%)</p>
<p><b>Common</b> (1% to 10%): Edema, epistaxis, mouth ulceration, dry mouth, mucosal inflammation, gingival infection, hiccups</p>
<p><b>Uncommon</b> (0.1% to 1%): Fatal hemorrhage, cerebral/intracranial hemorrhage, infections (with or without neutropenia), infectious peritonitis, menorrhagia, metrorrhagia, oropharyngeal pain</p>
<p><b>Postmarketing reports</b>: Infections (with or without neutropenia)<sup>[Ref]</sup></p><p>-RCC: The most common hemorrhagic events were hematuria, epistaxis, hemoptysis, and rectal hemorrhage.</p>
<p>-STS: The most common hemorrhagic events were epistaxis, mouth hemorrhage, and anal hemorrhage.</p>
<p>-Edema events included peripheral edema, eye edema, localized edema, and face edema.<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Increased creatinine (up to 26%), proteinuria (up to 12%)</p>
<p><b>Common</b> (1% to 10%): Increased urea</p>
<p><b>Uncommon</b> (0.1% to 1%): Nephrotic syndrome, thrombotic microangiopathy (TMA)</p>
<p><b>Postmarketing reports</b>: Thrombotic microangiopathy (TMA)<sup>[Ref]</sup></p><p>-TMA included thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS).<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (up to 59%), nausea (up to 56%), vomiting (up to 33%), gastrointestinal pain (up to 23%), abdominal pain (up to 14%), mucositis (up to 12%), stomatitis (up to 11%)</p>
<p><b>Common</b> (1% to 10%): Dyspepsia, flatulence, abdominal distension</p>
<p><b>Uncommon</b> (0.1% to 1%): Perforation or fistula, fatal perforations, hematochezia, melena, frequent bowel movements, hematemesis, pancreatitis, peritonitis</p>
<p><b>Postmarketing reports</b>: Pancreatitis, flatulence<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Fatigue (up to 65%), dysgeusia (up to 28%), headache (up to 23%), dizziness (up to 11%)</p>
<p><b>Common</b> (1% to 10%): Insomnia, dysphonia, lethargy, paresthesia, peripheral sensory neuropathy, chills</p>
<p><b>Uncommon</b> (0.1% to 1%): Hypoesthesia, somnolence, mucous membrane disorder, cerebral infarction, transient ischemic attack, cerebrovascular accident, ischemic stroke, posterior reversible encephalopathy syndrome/reversible posterior leukoencephalopathy syndrome (PRES/RPLS)</p>
<p><b>Postmarketing reports</b>: PRES/RPLS<sup>[Ref]</sup></p><p>-Dysgeusia included ageusia and hypogeusia.<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Common</b> (1% to 10%): Hypothyroidism, increased thyroid stimulating hormone</p>
<p><b>Uncommon</b> (0.1% to 1%): Abnormal thyroid function test<sup>[Ref]</sup></p><h3>General</h3><p>-Renal cell carcinoma (RCC): The most commonly observed adverse reactions (20% or more) were diarrhea, hypertension, hair color change, nausea, fatigue, anorexia, and vomiting.</p>
<p></p>
<p>-Soft tissue sarcoma (STS): The most commonly observed adverse reactions (20% or more) were fatigue, diarrhea, nausea, decreased weight, hypertension, decreased appetite, vomiting, tumor pain, hair color changes, musculoskeletal pain, headache, dysgeusia, dyspnea, and skin hypopigmentation.<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Hair color changes (up to 39%), skin hypopigmentation (up to 21%), exfoliative rash (up to 18%), palmar-plantar erythrodysesthesia syndrome (up to 18%), alopecia (up to 12%), rash (up to 11%)</p>
<p><b>Common</b> (1% to 10%): Dry skin, skin depigmentation, nail disorder, pruritus, erythema, hyperhidrosis</p>
<p><b>Uncommon</b> (0.1% to 1%): Skin exfoliation, photosensitivity reaction, erythematous rash, skin disorder, macular rash, pruritic rash, vesicular rash, papular rash, skin ulcer<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Hematuria<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Leukopenia (up to 44%), lymphocytopenia (up to 43%), thrombocytopenia (up to 36%), neutropenia (up to 34%), anemia (up to 27%)</p>
<p><b>Common</b> (1% to 10%): Decreased white blood cell count</p>
<p><b>Uncommon</b> (0.1% to 1%): Decreased platelet count<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Decreased weight (up to 48%), increased glucose (up to 45%), decreased appetite (up to 40%), increased albumin (up to 34%), decreased albumin (up to 34%), decreased phosphorus (up to 34%), decreased calcium (up to 33%), decreased sodium (up to 31%), increased potassium (up to 27%), decreased magnesium (up to 26%), anorexia (up to 22%), decreased glucose (up to 17%)</p>
<p><b>Common</b> (1% to 10%): Increased lipase, increased amylase, dehydration, abnormal blood cholesterol<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Musculoskeletal pain (up to 23%), myalgia (up to 23%), asthenia (up to 14%)</p>
<p><b>Common</b> (1% to 10%): Arthralgia, muscle spasms<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Blurred vision</p>
<p><b>Uncommon</b> (0.1% to 1%): Eyelash discoloration</p><h3>Oncologic</h3><p><b>Frequency not reported</b>: Increased toxicity and mortality with other cancer therapies</p><p>-Fatal toxicities including pulmonary hemorrhage, gastrointestinal hemorrhage, and sudden death have occurred when used with other cancer agents.</p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Dyspnea (up to 20%), cough (up to 17%)</p>
<p><b>Common</b> (1% to 10%): Pneumothorax</p>
<p><b>Uncommon</b> (0.1% to 1%): Rhinorrhea<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_3">3. "Product Information. Votrient (pazopanib)." GlaxoSmithKline, Research Triangle Park, NC. </p></div>
<div class="more-resources" id="moreResources">
<h2>More about Votrient (pazopanib)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>76 Reviews</li>
<li>Drug class: VEGF/VEGFR  inhibitors</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Votrient &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Soft Tissue Sarcoma</li>
<li>Renal Cell Carcinoma</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to pazopanib: oral tablet</i></p><h3>Hepatic</h3><p>-ALT and AST elevations occurred early in the treatment course; 92.5% of all transaminase elevations of any grade occurred in the first 18 weeks.</p><p>-Hepatic failure was the cause of death for 0.2% of RCC patients and 0.4% of STS patients.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Increased ALT (up to 53%), increased AST (up to 53%), increased total bilirubin (up to 36%), increased alkaline phosphatase (up to 32%)</p><p><b>Common</b> (1% to 10%): Abnormal hepatic function, hepatotoxicity, decreased alkaline phosphatase, increased gamma-glutamyltransferase (GGT), abnormal liver function test </p><p><b>Uncommon</b> (0.1% to 1%): Jaundice, drug-induced liver injury, hepatic failure, increased hepatic enzyme</p><p><b>Postmarketing reports</b>: Increased GGT<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p>-A majority of the patients with myocardial dysfunction had concurrent hypertension which may have exacerbated cardiac dysfunction in patients at risk possibly by increasing cardiac afterload.</p><p>-Cardiac dysfunction included left ventricular dysfunction, cardiac failure, and restrictive cardiomyopathy.</p><p>-Venous thromboembolic events included deep vein thrombosis, pulmonary embolism, and thrombosis terms.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Hypertension (up to 42%), myocardial dysfunction (up to 11%), chest pain (up to 10%)</p><p><b>Common</b> (1% to 10%): Venous thromboembolic events, cardiac dysfunction, bradycardia, QT prolongation, myocardial infarction or ischemia, hot flush, flushing</p><p><b>Uncommon</b> (0.1% to 1%): Torsades de pointes, congestive heart failure, fatal arterial thromboembolic events, hypertensive crisis<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Tumor pain (up to 32%), hemorrhagic events (up to 13%)</p><p><b>Common</b> (1% to 10%): Edema, epistaxis, mouth ulceration, dry mouth, mucosal inflammation, gingival infection, hiccups</p><p><b>Uncommon</b> (0.1% to 1%): Fatal hemorrhage, cerebral/intracranial hemorrhage, infections (with or without neutropenia), infectious peritonitis, menorrhagia, metrorrhagia, oropharyngeal pain</p><p><b>Postmarketing reports</b>: Infections (with or without neutropenia)<sup>[Ref]</sup></p><p>-RCC: The most common hemorrhagic events were hematuria, epistaxis, hemoptysis, and rectal hemorrhage.</p><p>-STS: The most common hemorrhagic events were epistaxis, mouth hemorrhage, and anal hemorrhage.</p><p>-Edema events included peripheral edema, eye edema, localized edema, and face edema.<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Increased creatinine (up to 26%), proteinuria (up to 12%)</p><p><b>Common</b> (1% to 10%): Increased urea</p><p><b>Uncommon</b> (0.1% to 1%): Nephrotic syndrome, thrombotic microangiopathy (TMA)</p><p><b>Postmarketing reports</b>: Thrombotic microangiopathy (TMA)<sup>[Ref]</sup></p><p>-TMA included thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS).<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (up to 59%), nausea (up to 56%), vomiting (up to 33%), gastrointestinal pain (up to 23%), abdominal pain (up to 14%), mucositis (up to 12%), stomatitis (up to 11%)</p><p><b>Common</b> (1% to 10%): Dyspepsia, flatulence, abdominal distension</p><p><b>Uncommon</b> (0.1% to 1%): Perforation or fistula, fatal perforations, hematochezia, melena, frequent bowel movements, hematemesis, pancreatitis, peritonitis</p><p><b>Postmarketing reports</b>: Pancreatitis, flatulence<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Fatigue (up to 65%), dysgeusia (up to 28%), headache (up to 23%), dizziness (up to 11%)</p><p><b>Common</b> (1% to 10%): Insomnia, dysphonia, lethargy, paresthesia, peripheral sensory neuropathy, chills</p><p><b>Uncommon</b> (0.1% to 1%): Hypoesthesia, somnolence, mucous membrane disorder, cerebral infarction, transient ischemic attack, cerebrovascular accident, ischemic stroke, posterior reversible encephalopathy syndrome/reversible posterior leukoencephalopathy syndrome (PRES/RPLS)</p><p><b>Postmarketing reports</b>: PRES/RPLS<sup>[Ref]</sup></p><p>-Dysgeusia included ageusia and hypogeusia.<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Common</b> (1% to 10%): Hypothyroidism, increased thyroid stimulating hormone</p><p><b>Uncommon</b> (0.1% to 1%): Abnormal thyroid function test<sup>[Ref]</sup></p><h3>General</h3><p>-Renal cell carcinoma (RCC): The most commonly observed adverse reactions (20% or more) were diarrhea, hypertension, hair color change, nausea, fatigue, anorexia, and vomiting.</p><p></p><p>-Soft tissue sarcoma (STS): The most commonly observed adverse reactions (20% or more) were fatigue, diarrhea, nausea, decreased weight, hypertension, decreased appetite, vomiting, tumor pain, hair color changes, musculoskeletal pain, headache, dysgeusia, dyspnea, and skin hypopigmentation.<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Hair color changes (up to 39%), skin hypopigmentation (up to 21%), exfoliative rash (up to 18%), palmar-plantar erythrodysesthesia syndrome (up to 18%), alopecia (up to 12%), rash (up to 11%)</p><p><b>Common</b> (1% to 10%): Dry skin, skin depigmentation, nail disorder, pruritus, erythema, hyperhidrosis</p><p><b>Uncommon</b> (0.1% to 1%): Skin exfoliation, photosensitivity reaction, erythematous rash, skin disorder, macular rash, pruritic rash, vesicular rash, papular rash, skin ulcer<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Hematuria<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Leukopenia (up to 44%), lymphocytopenia (up to 43%), thrombocytopenia (up to 36%), neutropenia (up to 34%), anemia (up to 27%)</p><p><b>Common</b> (1% to 10%): Decreased white blood cell count</p><p><b>Uncommon</b> (0.1% to 1%): Decreased platelet count<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Decreased weight (up to 48%), increased glucose (up to 45%), decreased appetite (up to 40%), increased albumin (up to 34%), decreased albumin (up to 34%), decreased phosphorus (up to 34%), decreased calcium (up to 33%), decreased sodium (up to 31%), increased potassium (up to 27%), decreased magnesium (up to 26%), anorexia (up to 22%), decreased glucose (up to 17%)</p><p><b>Common</b> (1% to 10%): Increased lipase, increased amylase, dehydration, abnormal blood cholesterol<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Musculoskeletal pain (up to 23%), myalgia (up to 23%), asthenia (up to 14%)</p><p><b>Common</b> (1% to 10%): Arthralgia, muscle spasms<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Blurred vision</p><p><b>Uncommon</b> (0.1% to 1%): Eyelash discoloration</p><h3>Oncologic</h3><p><b>Frequency not reported</b>: Increased toxicity and mortality with other cancer therapies</p><p>-Fatal toxicities including pulmonary hemorrhage, gastrointestinal hemorrhage, and sudden death have occurred when used with other cancer agents.</p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Dyspnea (up to 20%), cough (up to 17%)</p><p><b>Common</b> (1% to 10%): Pneumothorax</p><p><b>Uncommon</b> (0.1% to 1%): Rhinorrhea<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_3">3. "Product Information. Votrient (pazopanib)." GlaxoSmithKline, Research Triangle Park, NC. </p><h2>More about Votrient (pazopanib)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>76 Reviews</li>
<li>Drug class: VEGF/VEGFR  inhibitors</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Votrient &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Soft Tissue Sarcoma</li>
<li>Renal Cell Carcinoma</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>